By binding to CD38 antigen on MM cells surface, daratumumab promotes apoptosis of MM cells and activates immune mechanisms (antibody-dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP) and complement dependent cytotoxicity (CDC)) leading to MM cell death [8, 9]. Here, CD38 is linked to Miyoshi myopathy.